BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today highlighted its recent pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback